Eurocine Vaccines has completed dosing of its quadrivalent influenza vaccine candidate, Immunose™ FLU, in the second clinical study

– In the perspective of this year’s severe influenza outburst we are pleased to have chosen the broader quadrivalent, rather than trivalent, vaccine for our product candidate, says Dr. Anna\-Karin\s+Maltais, Chief Scientific Officer.

-The elderly always suffer most from influenza disease and we believe that we can offer a better and more convenient vaccine in this segment. This, without loosing sight of our vision, to offer the first nasal influenza vaccine for children younger than 2 years, adds Hans\s+Arwidsson, CEO of Eurocine Vaccines.

The strategy behind this present study, and its design, was presented in a previous news release dated February 7th, 2018 and can be read at;

https://www.eurocine-vaccines.com/en/eurocine-vaccines-takes-advantage-of-yet-another-influenza-season-launching-its-second-clinical-study-on-immunose-flu/
 

The progress of the study can also be followed at; https://clinicaltrials.gov
Results are expected second half of 2018.

Vill du följa Eurocine Vaccines utveckling lättare?

Ta del del av pressreleaser, nyheter och artiklar kring vaccinering och influensa.

Starta din prenumeration här »